INTRODUCTION
============

Opioid use disorder (OUD) is highly prevalent and leads to substantial social and health-related costs \[[@b1-cpn-18-136],[@b2-cpn-18-136]\]. Compromised inhibitory control, memory, and post-error behavioral adjustment were constantly found in individuals with addiction \[[@b3-cpn-18-136]\]. Therefore, deficit in cognitive function might have a major role in driving OUD \[[@b4-cpn-18-136]\]. Studies have reported that patients with OUD had impaired cognitive and executive functions \[[@b5-cpn-18-136]\]. Both former and current opioid abusers had impaired cognitive flexibility, inhibition control, and working memory \[[@b6-cpn-18-136]\] in addition to impaired processing and psychomotor speed, verbal learning, and verbal fluency \[[@b7-cpn-18-136]\]. The severity of cognitive impairments was also related to the treatment outcomes in patients with OUD \[[@b8-cpn-18-136],[@b9-cpn-18-136]\]. However, the pathophysiological mechanisms underlying these cognitive deficits associated with long-term heroin use are still unknown. Therefore, it is important to investigate the underlying etiology for cognitive dysfunction in OUD.

In addition to affecting neurocognitive functions, genetic factors might also contribute to the development of OUD \[[@b10-cpn-18-136]\]. We reported that the *aldehyde dehydrogenase 2* (*ALDH2*) gene was associated with OUD in a Han Chinese population \[[@b11-cpn-18-136]\]. The *ALDH2* gene is on chromosome 12q24. A single nucleotide polymorphism (rs671, G→A) in exon 12 leads to an amino acid substitution from glutamic acid (G) to lysine (A) in the ALDH2 enzyme. The ALDH enzymes have been classified as class 1 (low *Km*, cytosolic, including ALDH1), class 2 (low *Km*, mitochondrial, including ALDH2) and class 3 (high-*Km*, including ALDH3), based on kinetic properties and sequence similarities \[[@b12-cpn-18-136]\]. The most important enzyme for acetaldehyde oxidation are mitochondrial ALDH2, which were expressed in a larger number of tissues than ALDH1, with highest levels in liver, kidney, muscle, and heart, and also in brain \[[@b13-cpn-18-136]\]. ALDH2 also metabolizes dopamine and is responsible for DOPAL (3,4-dihydroxyphenylacetaldehyde) metabolism to DOPAC (3,4-dihydroxyphenylacetic acid) \[[@b14-cpn-18-136]\]. The G allele (*ALDH2* \**1* ) encodes an active form of the ALDH2 enzyme to metabolize DOPAL, and the A allele (*ALDH2* \**2* ) encodes an inactive form to metabolize DOPAL \[[@b15-cpn-18-136]\]. Other studies \[[@b16-cpn-18-136]\] hypothesized that the *ALDH2* gene is associated with OUD through dopamine metabolism, that DOPAL accumulates in opioid users with the *ALDH2* \**2* allele, and that this leads to opioid addiction. However, the actual mechanisms are unknown. The *ALDH2* polymorphisms are related to Alzheimer's disease, which implies an association between ALDH2 polymorphisms and memory function \[[@b17-cpn-18-136],[@b18-cpn-18-136]\]. Moreover, *ALDH2* polymorphisms are associated with the effects of alcohol on various neurophysiological and psychomotor functions \[[@b19-cpn-18-136],[@b20-cpn-18-136]\]. All these studies \[[@b17-cpn-18-136]--[@b20-cpn-18-136]\] hypothesized that the *ALDH2* gene polymorphisms affect aldehyde metabolism and cognitive function. We therefore hypothesize that the *ALDH2* gene affects the cognitive functions in patients with OUD as it does in alcohol abusers, and that it leads to the underlying cognitive deficits in OUD.

In the present study, we investigated the effect of *ALDH2* genotypes on neuropsychological performance, focus on attention, inhibition control, and memory function, all of which are central to long-term recovery in addiction \[[@b21-cpn-18-136]\], and in patients with OUD who have undergone methadone maintenance therapy (MMT). Because studies have reported that memory function might change after two months of MMT \[[@b22-cpn-18-136]\], a longitudinal study controlled for potential confounding factors is more suitable for assessing the association between changes in neuropsychological function and the *ALDH2* gene polymorphisms. We therefore used a longitudinal study to assess the effects of the *ALDH2* gene in changes of the cognitive performance of OUD patients who had undergone 12 weeks of MMT.

METHODS
=======

Participants
------------

The research protocol was approved by the Institutional Review Board for the Protection of Human Subjects at National Cheng Kung University Hospital (no. B-BR-103-027-T). The study was done in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The procedures were fully explained to each participant before they were asked to sign an informed consent. OUD patients were recruited from the MMT program. Each patient was initially interviewed by an attending psychiatrist and then by a research team member well trained in using the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) \[[@b23-cpn-18-136]\] criteria and the Chinese Version of the Mini International Neuropsychiatric Interview (MINI) \[[@b24-cpn-18-136]\]. The MINI was used because completing 4--6 hours of structured interviews, such as the Chinese Version of the Modified Schedule of Affective Disorder and Schizophrenia-Lifetime (SADS-L) \[[@b25-cpn-18-136]\], is difficult for OUD patients. The MINI has good reliability and has been widely used in clinical trials and epidemiological studies \[[@b26-cpn-18-136]\], and its interrater reliability in Chinese Version was approximately 0.75 in previous studies \[[@b27-cpn-18-136],[@b28-cpn-18-136]\]. Inclusion criteria were being an adult male or female between 18 and 65 years old who met the DSM-IV criteria for current opioid dependence and who used opioids daily. Exclusion criteria were having a cognitive disorder, being pregnant or nursing an infant, or having a history of one or more uncontrolled major chronic illnesses like diabetes mellitus and hypertension.

We recruited 86 OUD patients at the beginning of our study. At baseline, each patient was assessed for *ALDH2* genotypes and for cognitive function using the Connors' Continuous Performance Tests (CPT) and Wechsler Memory Scale-Revised (WMS-R). Their MMT and psychosocial interventions were maintained during the follow-up. After 12 weeks of follow-up, we reassessed their CPT and WMS-R.

Blood Samples and Genotyping
----------------------------

Twenty milliliters of venous blood was drawn from each participant, and DNA was extracted. Genotyping of the *ALDH2* gene was determined using protocols described elsewhere \[[@b29-cpn-18-136]\].

Neurocognitive Test
-------------------

The Conners' Continuous Performance Test (CPT) \[[@b30-cpn-18-136]\] was used to assess the maintenance of focused attention and inhibitory control. An adequate level of arousal, combined with executive control to resist distraction and inhibit responses to stimuli resembling targets, were required to perform correctly. Respondents are asked to press the space bar on a computer keyboard when any letter other than "X" appeared. The interstimulus intervals were 1, 2, and 4 seconds, and display time was 250 ms. The CPT produces a standard set of performance measures that include the number of errors of omission and errors of commission. (1) Errors of omission occurred when the patient did respond to the target stimulus. (2) Errors of commission occurred when the patient responded to a nontarget (X) stimulus. (3) Hit reaction time (HRT) represents the mean response time (ms) for all target responses over the full six trial blocks. (4) HRT standard error (HRT SE) represents the consistency of response times and expresses the SE response to targets \[[@b31-cpn-18-136]\]. The split-half reliability is 0.66--0.95, and the test-retest reliability after three months is 0.55--0.84. The CPT has good reliability and validity for Han Chinese living in Taiwan \[[@b32-cpn-18-136]\].

The WMS-R, a major assessment of cognitive function \[[@b33-cpn-18-136]\], assesses all factors of memory. The WMS-R consists of 13 subtests and five indices (General Memory, Verbal Memory, Visual Memory, Attention/Concentration, and Delayed Recall). The Information and Orientation Questions (the first subtest) were used to screen for disorientation and intact sensory functioning. Attention and working memory were assessed using the Attention/Concentration index subtests \[[@b34-cpn-18-136]\]. The index-score reliability coefficients range from 0.70 to 0.90 \[[@b35-cpn-18-136]\]. The test-retest reliability after 2 to 12 weeks is 0.62--0.82 \[[@b33-cpn-18-136]\]. Interrater reliability is more than 0.9 \[[@b36-cpn-18-136]\].

Statistical Analysis
--------------------

The differences in the frequency of the *ALDH2* \**1*/\**1* (*ALDH2* active) and *ALDH2* \**1* /\**2*+\**2* /*2* (*ALDH2* inactive) genotypes between patient and control groups were calculated using a χ^2^ test (two-tailed). Fisher's exact test was substituted for the χ^2^ test when values were smaller than expected (\< 5). Student's *t* test was used to estimate differences in mean age between two groups. We assigned patients with the *ALDH2* \**1*/\**2* and \**2* /\**2* genotypes to the same group, *ALDH2* inactive group, because the aldehyde metabolic effect as the *ALDH2* \**2* / \**2*-encoded enzyme is inactive, and the *ALDH2* \**1*/\**2*-encoded enzyme has an aldehyde metabolite rate of only 1/10 that of the *ALDH2* \**1*/\**1* genotype \[[@b37-cpn-18-136]\]. Additionally, because there were repeated assessments, the generalized estimating equation (GEE) method \[[@b38-cpn-18-136]\] was used for multivariate linear regression in repeated-measures analyses that accommodate randomly missing data \[[@b39-cpn-18-136]\]. In the current study, GEE analysis was used to investigate the changes in CPT and WMS-R individual scores from baseline to endpoint, and in the correlations with the *ALDH2* genotypes. Time effects during the 12-week MMT, age, sex, methadone dose, disease duration, and psychiatric comorbidities were covariables. Significance was set at *p* \< 0.05. SPSS 18.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

All authors have read and approved the manuscript and declared that: (i) no support, financial or otherwise, has been received from any organization that may have an interest in the submitted work; and (ii) there are no other relationships or activities that could appear to have influenced the submitted work.

RESULTS
=======

We enrolled 86 participants in our study, and 61 completed the assessments. At baseline, 46.5% of the patients had the *ALDH2* active genotype, and, at the endpoint, 42.6% had it. Genotype distribution of the *ALDH2* loci was in Hardy--Weinberg equilibrium at baseline and endpoint (*p* \> 0.1). The demographic data of age, sex, disease duration, methadone dose, psychiatric comorbidities, and neurocognitive function were assessed using CPT and WMS-R. At baseline, there were no significant differences between the *ALDH2* active and inactive genotypes in demographic data or CPT and WMS-R scores ([Table 1](#t1-cpn-18-136){ref-type="table"}). However, OUD patients with the *ALDH2* active genotype had significantly higher HRT T-scores and WMS-R visual memory index than did patients with the *ALDH2* inactive genotypes at the endpoint (*p* = 0.03 and *p* = 0.006, respectively) ([Table 1](#t1-cpn-18-136){ref-type="table"}).

After covarying for age, sex, methadone dose, disease duration, treatment duration, and psychiatric comorbidities, the GEE analysis showed significantly different changes of commission and HRT T-scores on the CPT and WMS-R visual memory index in OUD patients with different *ALDH2* genotypes after 12 weeks of MMT (*p* = 0.03, 0.04, and 0.03, respectively) ([Table 2](#t2-cpn-18-136){ref-type="table"}).

Furthermore, OUD patients with the *ALDH2* inactive genotypes had significantly higher commission T- and significantly lower HRT T-scores than did those with the *ALDH2* active genotype during MMT ([Figs. 1](#f1-cpn-18-136){ref-type="fig"}, [2](#f2-cpn-18-136){ref-type="fig"}, [Table 2](#t2-cpn-18-136){ref-type="table"}). OUD patients with the *ALDH2* inactive genotypes also had significantly lower scores on the WMS-R visual memory index than did OUD patients with the *ALDH2* active genotype ([Fig. 3](#f3-cpn-18-136){ref-type="fig"}, [Table 2](#t2-cpn-18-136){ref-type="table"}).

DISCUSSION
==========

This is the first study that shows the effect of the *ALDH2* gene polymorphisms on cognitive functions in OUD patients undergoing MMT. We found that OUD patients with the *ALDH2* inactive genotypes performed significantly less well in the attention and memory domain than did patients with the *ALDH2* active genotype. OUD patients with *ALDH2* inactive genotypes might react more impulsively, make more commission errors and have lower reaction times, and have poorer visual memory function during MMT than do those with the *ALDH2* active genotype. This suggests that the *ALDH2* gene is associated with the development and treatment outcomes in OUD patients.

Because ALDH is the major enzyme that metabolizes acetaldehyde, it is well-known for its influence on drinking behavior and for the risk of developing alcohol dependence \[[@b40-cpn-18-136],[@b41-cpn-18-136]\]. ALDH2 is also one of the major ALDH isozymes that catalyzes the oxidation of dopamine \[[@b37-cpn-18-136]\], which is an important neurotransmitter for addiction. Dopamine is metabolized by monoamine oxidase and forms DOPAL (3,4-dihydroxyphenyl-acetaldehyde), a toxic dopamine metabolite \[[@b42-cpn-18-136],[@b43-cpn-18-136]\]. DOPAL is subsequently oxidized to DOPAC (3,4-dihydroxyphenylaceticacid) by ALDH \[[@b42-cpn-18-136],[@b44-cpn-18-136]\]. Therefore, the *ALDH2* gene-encoded enzyme is functionally associated with the level of DOPAL \[[@b42-cpn-18-136],[@b44-cpn-18-136]\]. Patients with *ALDH2* inactive genotypes might accumulate a higher level of DOPAL because the *ALDH2* inactive genotypes-encoded enzymes are inactive forms that metabolize DOPAL \[[@b44-cpn-18-136]\]. Because ALDH2 is widely expressed in the frontal and temporal cortex, hippocampus, midbrain, basal ganglia, cerebellum, glial cells, and neurons \[[@b45-cpn-18-136]--[@b47-cpn-18-136]\], the accumulation of DOPAL can consequently impair neurocognitive function, e.g., memory function. Animal studies report that ALDH2 knockdown (*ALDH2* ^−/−^) mice had significantly higher-than-normal hippocampal levels of toxic protein and peptides, and had age-related memory deficits and brain atrophy \[[@b17-cpn-18-136]\]. Human meta-analysis study also showed that *ALDH2* inactive genotypes increased the risk of Alzheimer's disease in East Asian men \[[@b48-cpn-18-136]\]. Consistent with other findings, we found that OUD patients with the *ALDH2* inactive genotypes had poorer visual memory function. Taking all these data together supports the notion that the *ALDH2* \**2* allele is associated with impaired memory function in OUD patients.

Impulsivity, associated with motor or response dis-inhibition, is commonly associated with addiction \[[@b49-cpn-18-136]\]. In addition, increased toxic aldehyde levels were found in attention-deficit hyperactivity disorder \[[@b50-cpn-18-136]\], which partly suggested that the deficient ALDH2 enzyme that causes aldehyde to accumulate might be associate with inattention and impulsivity. We previously reported that impulsive personality traits like novelty seeking were affected by the *ALDH2* genotypes in heroin-dependent patients \[[@b51-cpn-18-136]\]. Heroin-dependent patients with at least one *ALDH2* \**2* allele (\**1*/\**2* or \**2* /\**2* genotype) had significantly higher novelty seeking scores \[[@b51-cpn-18-136]\]. We extended the scope of other studies by objectively measuring the cognitive function associated with inhibitory controls and attention. We found that, on the CPT, OUD patients with the *ALDH2* inactive genotypes reacted more impulsively and had more attentional problems, more commission errors, and lower reaction times than did those with the *ALDH2* active genotype. Response-inhibition deficits, specifically those related to inattention and impulsive behaviors, have been related to poorer clinical treatment outcomes in addicted patients \[[@b52-cpn-18-136]\]. Therefore, OUD patients with the *ALDH2* inactive genotypes might have poorer outcomes after they undergo MMT.

Because the ALDH2 enzyme is required to metabolize aldehyde, it is important to highlight that ALDH2 deficiency is one of the most common enzymopathies in humans: it affects an estimated 560 million (8%) of the world population \[[@b53-cpn-18-136]\]. ALDH2 deficiency is endemic in East Asia and is common in China, Japan, Korea, Taiwan, and Singapore \[[@b54-cpn-18-136]\]. The highest ALDH2 deficiency prevalence is in Taiwan: about half of its Han Chinese population has the *ALDH2* \**2* allele \[[@b40-cpn-18-136],[@b41-cpn-18-136]\]. The ethnicity difference is important for studying the risk of developing OUD and the treatment outcomes \[[@b55-cpn-18-136],[@b56-cpn-18-136]\]. Unfortunately, other studies focused only on the effects of *ALDH2* gene polymorphisms in modulating alcohol-related cognitive function \[[@b19-cpn-18-136],[@b20-cpn-18-136]\] and ignored the changes caused by other classes of substance abuse. Kim *et al*. \[[@b19-cpn-18-136]\] found that the psychomotor performance of patients with *ALDH2* \**1*/\**2* was significantly poorer than that of those with the *ALDH2* \**1*/\**1* genotype after alcohol consumption. Our study extended the research population OUD patients and agreed with the findings of Kim *et al*. \[[@b19-cpn-18-136]\], which suggested that the *ALDH2* \**2* allele was associated with substance-abuse-related neuropsychological function impairments. Additional studies to investigate whether *ALDH2* gene polymorphisms also affect cognitive functions in other classes of substance use disorders, such as stimulants, might be needed.

Limitations
-----------

Our study has some limitations. This is the first study that tests the hypothesis that the *ALDH2* gene polymorphisms are associated with neuropsychological function in OUD patients undergoing MMT. The sample size was modest; larger samples are needed. Although we controlled for some factors that might affect changes in cognitive function, other factors, e.g., the severity of comorbid psychiatric disorders, might also have affected our results. In addition, all our patients were undergoing MMT, which might have affected their attention and memory performances. Although we tried to control for the methadone dose in our analysis to reduce its effect, additional studies are required to generalize our results to abstinent former opioid abusers who did not undergo MMT. We excluded those who took other psychiatric medication, except methadone, in this study. However, some of the patients may still take other psychotrophic agents by themselves without informing us, which may also affect their results in neuropsychiatric tests. Therefore, our findings should be interpreted with caution.

Conclusion
----------

OUD patients with the *ALDH2* inactive genotypes performed worse in cognitive domains of attention, impulse control, and memory than did those with the *ALDH2* active genotype. We conclude that the *ALDH2* gene is important in OUD and might be associated with MMT outcomes in OUD patients. Our findings must be replicated in larger samples and studies with longer follow-ups.

The study was supported by research grants from the Ministry of Science and Technology (NSC101-2314-B-006-063-MY3 to RBL and MOST 106-2314-B-006-037, MOST-107-2314-B-006-067 to TYW), from the Ministry of Health and Welfare (DOH 98-TD-I-111-DD004 to RBL and MOHW107-TDU-B-211-123003, MOHW108-TD U-B-211-133003 to TYW), from the National Health Research Institutes (07A1-NPPP08-021 to RBL), from the National Cheng Kung University Project of Promoting Academic Excellence & Developing World Class Research Centers, Taiwan (to RBL) and from the project of Integrated Drug Addiction Treatment Center, Ministry of Health and Welfare, Taiwan (to TYW).

**Conflicts of Interest**

All authors declare that they have no conflicts of interest.

**Author Contributions**

TYW and RBL designed the study and wrote the protocol. YHC, PSC, YKY and CHC supervised the laboratory work and the data analyses. TYW, SYL, KCC, SLC, NST, SYH, IHL, SHC, and RBL recruited participants. PWL wrote the first draft of the manuscript. TYW reviewed the literature and contributed to the discussion. All authors contributed to and reviewed the final version of the manuscript.

![Changes in CPT commission T-scores in OUD patients with different *ALDH2* genotypes during 12 weeks of MMT.\
CPT, Conner's Continuous Performance Test; OUD, opioid use disorder; *ALDH2*, *aldehyde dehydrogenase 2* ; MMT, methadone maintenance therapy.](cpn-18-136f1){#f1-cpn-18-136}

![Changes in CPT HRT T-scores in OUD patients with different *ALDH2* genotypes during 12 weeks of MMT.\
CPT, Conner's continuous performance test; HRT, hit reaction time; OUD, opioid use disorder; *ALDH2*, *aldehyde dehydrogenase 2* ; MMT, methadone maintenance therapy.](cpn-18-136f2){#f2-cpn-18-136}

![Changes in WMS-R visual memory index in OUD patients with different *ALDH2* genotypes during 12 weeks of MMT.\
WMS-R, Wechsler memory scale-revised; OUD, opioid use disorder; *ALDH2*, *aldehyde dehydrogenase 2* ; MMT, methadone maintenance therapy.](cpn-18-136f3){#f3-cpn-18-136}

###### 

Demographic data and neuropsychological tests in patients with opioid use disorder

  Variable                         Baseline                                                  Endpoint                                                                                                                                                                               
  -------------------------------- --------------------------------------------------------- --------------------------------------------------------- ------ ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------
  Age (yr)                         37.4 ± 9.2                                                37.1 ± 5.6                                                0.88   36.5 ± 9.2                                                 36.5 ± 5.7                                                 0.98
  Sex (male/female)                33/7                                                      41/5                                                      0.38   24/2                                                       30/5                                                       0.42
  Disease duration (yr)            6.7 ± 6.0[a](#tfn3-cpn-18-136){ref-type="table-fn"}       7.2 ± 5.2[b](#tfn4-cpn-18-136){ref-type="table-fn"}       0.69   5.7 ± 5.9                                                  6.7 ± 4.8                                                  0.49
  Methadone dose (mg)              32.13 ± 27.78                                             34.13 ± 22.62                                             0.71   39.81 ± 20.37                                              40.06 ± 25.57                                              0.97
  Psychiatric comorbidities        11 (27.5)                                                 12 (26.1)                                                 0.88   9 (34.6)                                                   11 (31.4)                                                  0.79
  CPT                                                                                                                                                                                                                                                                               
   Omission T-scores               58.91 ± 41.68                                             61.20 ± 32.87                                             0.77   53.68 ± 15.56                                              64.04 ± 46.89                                              0.28
   Commission T-scores             47.38 ± 11.58                                             50.50 ± 11.38                                             0.21   45.76 ± 10.97                                              51.28 ± 11.81                                              0.07
   HRT T-scores                    52.00 ± 14.48                                             47.91 ± 14.16                                             0.19   54.95 ± 14.75                                              46.76 ± 13.31                                              0.03[\*](#tfn8-cpn-18-136){ref-type="table-fn"}
   HRT SE T-scores                 53.49 ± 13.86                                             52.80 ± 17.20                                             0.84   58.35 ± 12.44                                              53.77 ± 14.03                                              0.19
  WMS-R                                                                                                                                                                                                                                                                             
   Verbal Memory Index             92.90 ± 16.44                                             90.07 ± 16.49                                             0.44   101.40 ± 20.86                                             98.18 ± 20.14                                              0.61
   Visual Memory Index             98.95 ± 11.75                                             94.47 ± 14.97                                             0.14   113.15 ± 16.38                                             99.23 ± 14.62                                              0.006[\*](#tfn8-cpn-18-136){ref-type="table-fn"}
   General Memory Index            95.23 ± 17.56                                             90.14 ± 16.65                                             0.18   106.15 ± 19.74                                             99.00 ± 19.94                                              0.25
   Attention/Concentration Index   103.43 ± 15.47                                            102.60 ± 13.39                                            0.80   110.50 ± 11.82                                             106.45 ± 15.27                                             0.35
   Delayed Recall Index            97.34 ± 15.77[c](#tfn5-cpn-18-136){ref-type="table-fn"}   96.11 ± 16.83[c](#tfn5-cpn-18-136){ref-type="table-fn"}   0.75   106.11 ± 18.22[d](#tfn6-cpn-18-136){ref-type="table-fn"}   102.19 ± 21.13[e](#tfn7-cpn-18-136){ref-type="table-fn"}   0.54

Values are presented as mean ± standard deviation, number only, or number (%). *ALDH2* active genotype: *ALDH2*\**1*/\**1* genotype; *ALDH2* inactive genotypes: *ALDH2*\**1*/\*2 and \**2*/\**2* genotypes.

*ALDH2*, *aldehyde dehydrogenase 2*; CPT, Conner's continuous performance test; HRT, hit reaction time; SE, standard error; WMS-R, wechsler memory scale-revised.

n = 37;

n = 41;

n = 35;

n = 19;

n = 21.

*p* \< 0.05.

###### 

Comparisons of the changes in neuropsychological tests after 12 weeks of MMT in groups with different *ALDH2* gene polymorphisms

  Neuropsychological tests         *ALDH2* inactive genotypes          
  -------------------------------- ---------------------------- ------ --------------------------------------------------
  CPT                                                                  
   Omission T-scores               7.07                         1.60   0.21
   Commission T-scores             4.56                         4.67   0.03[\*](#tfn11-cpn-18-136){ref-type="table-fn"}
   HRT T-scores                    −5.18                        4.23   0.04[\*](#tfn11-cpn-18-136){ref-type="table-fn"}
   HRT SE T-scores                 −2.03                        0.64   0.42
  WMS-R                                                                
   Verbal Memory Index             −3.29                        1.27   0.26
   Visual Memory Index             −5.42                        4.89   0.03[\*](#tfn11-cpn-18-136){ref-type="table-fn"}
   General Memory Index            −5.01                        2.80   0.09
   Attention/Concentration Index   −0.33                        0.02   0.90
   Delayed Recall Index            −2.55                        0.54   0.46

Reference group: *ALDH2* active genotype. Covarying for age, sex, methadone dose, disease duration, visits, and psychiatric comorbidities.

MMT, methadone maintenance therapy; *ALDH2*, *aldehyde dehydrogenase 2*; CPT, Conner's continuous performance test; HRT, hit reaction time; SE, standard error; WMS-R, wechsler memory scale-revised.

*p* \< 0.05.
